Multi-elemental analysis of serum and amyloid fibrils in familial amyloid polyneuropathy patients

Amyloid

Volumn 15, Issue 2, 2008, Pages 108-116

  Susuki, Seiko ^a   Ando, Yukio ^b   Sato, Takashi ^a   Nishiyama, Masami ^a   Miyata, Masanori ^a   Suico, Mary Ann ^a   Shuto, Tsuyoshi ^a   Kai, Hirofumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Amyloid; FAP; FAP patients; ICP MS; Metals; Serum

Indexed keywords

AMYLOID; ARSENIC; BARIUM; CESIUM; CHROMIUM; COPPER; IRON; LEAD; MANGANESE; PREALBUMIN; RUBIDIUM; STRONTIUM; VANADIUM; ZINC; METAL;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; AMINO ACID SUBSTITUTION; BLOOD; CASE CONTROL STUDY; CHEMISTRY; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; POINT MUTATION;

ADULT; AMINO ACID SUBSTITUTION; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METALS; MIDDLE AGED; POINT MUTATION; PREALBUMIN;

EID: 45549093609     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120802006013     Document Type: Article

References (35)

1. Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y. Polyneuritic amyloidosis in a Japanese family. Arch Neurol 1968;18:593-602.
2. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-1062.
3. Ando Y, Ando E, Ohlsson PI, Olofsson A, Sandgren O, Suhr O, Terazaki H, Obayashi K, Lundgren E, Ando M, Negi A. Analysis of transthyretin amyloid fibrils from vitreous samples in familial amyloidotic polyneuropathy (Val30Met). Amyloid 1999;6:119-123.
4. Haraoka K, Ando Y, Ando E, Sandgren O, Hirata A, Nakamura M, Terazaki H, Tajiri T, Tanoue Y, Sun X, Okabe H, Tanihara H. Amyloid deposition in ocular tissues of patients with familial amyloidotic polyneuropathy (FAP). Amyloid 2002;9:183-189.
5. Schreiber G, Richardson SJ. The evolution of gene expression, structure and function of transthyretin. Comp Biochem Physiol B Biochem Mol Biol 1997;116:137-160.
6. Sousa MM, Saraiva MJ. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 2003;71:385-400.
7. Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007;274:1637-1650.
8. Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 2002;294:309-314.
9. Ando Y, Nyhlin N, Suhr O, Holmgren G, Uchida K, el Sahly M, Yamashita T, Terasaki H, Nakamura M, Uchino M, Ando M. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun 1997;232:497-502.
10. Contestabile A. Oxidative stress in neurodegeneration: mechanisms and therapeutic perspectives. Curr Top Med Chem 2001;1:553-568.
11. Finefrock AE, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 2003;51:1143-1148.
12. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 2000;4:184-191.
13. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 2005;146:1041-1059.
14. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998;273:12817-12826.
15. Miura T, Suzuki K, Kohata N, Takeuchi H. Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry 2000;39:7024-7031.
16. Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, Zhu X. Iron: The redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 2007;32:1640-1645.
17. Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I, Perugini M, White AR, Cherny RA, Masters CL, Barrow CJ, Collins SJ, Bush AI, Cappai R. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 2001;40:8073-8084.
18. Thackray AM, Knight R, Haswell SJ, Bujdoso R, Brown DR. Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochem J 2002;362:253-258.
19. Forte G, Bocca B, Senofonte O, Petrucci F, Brusa L, Stanzione P, Zannino S, Violante N, Alimonti A, Sancesario G. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm 2004;111:1031-1040.
20. Bomboi G, Marchione F, Sepe-Monti M, De Carolis A, Bianchi V, Medda E, Pino A, Bocca B, Forte G, D'Ippolito C, Giubilei F. Correlation between metal ions and clinical findings in subjects affected by Alzheimer's disease. Ann Ist Super Sanita 2005;41:205-212.
21. Forte G, Alimonti A, Pino A, Stanzione P, Brescianini S, Brusa L, Sancesario G, Violante N, Bocca B. Metals and oxidative stress in patients with Parkinson's disease. Ann Ist Super Sanita 2005;41:891-195.
22. Bocca B, Forte G, Petrucci F, Pino A, Marchione F, Bomboi G, Senofonte O, Giubilei F, Alimonti A. Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann Ist Super Sanita 2005;41:197-203.
23. 42 in senile plaque cores in Alzheimer's disease. J Alzheimers Dis 2006;10:173-177.
24. Sato T, Ando Y, Susuki S, Mikami F, Ikemizu S, Nakamura M, Suhr O, Anraku M, Kai T, Suico MA, Shuto T, Mizuguchi M, Yamagata Y, Kai H. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Lett 2006;580:491-491.
25. Goulle JP, Mahieu L, Castermant J, Neveu N, Bonneau L, Laine G, Bouige D, Lacroix C. Metal and metalloid multielementary ICP-MS validation in whole blood, plasma, urine and hair. Reference values. Forensic Sci Int 2005;153:39-44.
26. Bocca B, Forte G, Petrucci F, Senofonte O, Violante N, Alimonti A. Development of methods for the quantification of essential and toxic elements in human biomonitoring. Ann Ist Super Sanita 2005;41:165-170.
27. Ueda M, Ando Y, Haraoka K, Katsuragi S, Terasaki Y, Sugimoto M, Sun X, Uchino M. Aging and transthyretin-related amyloidosis: pathologic examinations in pulmonary amyloidosis. Amyloid 2006;13:24-30.
28. Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, Yamashita T, Ueda M, Okabe H, Sasaki Y, Tanihara H, Uchino M, Inomata Y. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation 2004;77:345-349.
29. Thylen C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. Embo J 1993;12:743-748.
30. FDA. Guidance for Industries. Bioanalytical Method Validation, US Department of Health and Human Services Food and Drug Administration. May 2001. Rockville, MD: CDER, 2001.
31. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol 2005;86:147-159.
32. Moreira PI, Siedlak SL, Aliev G, Zhu X, Cash AD, Smith MA, Perry G. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 2005;112:921-932.
33. Lynch T, Cherny RA, Bush AI. Oxidative processes in Alzheimer's disease: the role of Abeta-metal interactions. Exp Gerontol 2000;35:445-451.
34. Weaver J, Porasuphatana S, Tsai P, Cao GL, Budzichowski TA, Roman LJ, Rosen GM. The effect of divalent cations on neuronal nitric oxide synthase activity. Toxicol Sci 2004;81:325-331.
35. Sousa MM, Du Yan S, Fernandes R, Guimaraes A, Stern D, Saraiva MJ. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001;21:7576-7586.